A PHASE Ib STUDY EVALUATING THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) ADMINISTERED IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Protocol: 
AAAQ9045
Phase: 
I

A PHASE Ib STUDY EVALUATING THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) ADMINISTERED IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

The purpose of this study is to test the safety of the combination of the experimental drugs called atezolizumab and guadecitabine (not yet approved by the U.S. Food and Drug Administration [FDA] or any other regulatory authority outside the United States) to find out what effects, good or bad, the combination of atezolizumab and guadecitabine has on you.

Are you Eligible? (Inclusion Criteria)

1) Age >= 18 years
2) Disease progression or failure to achieve complete or partial response after
intensive cytotoxic
therapy
3) Patients cannot have received more than two prior intensive regimens (e.g.,
induction +
consolidation and one salvage therapy + consolidation).

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States